3 Firms Steer Obesity Drugmaker Corxel's $377M SPAC Deal
Obesity-focused biopharmaceutical company Corxel Pharmaceuticals Inc. on Monday unveiled plans to go public by merging with special-purpose acquisition company Amanat Acquisition Corp. in a deal expected to generate roughly $377 million...To view the full article, register now.
Already a subscriber? Click here to view full article